Aviceda Therapeutics is winding down after a Phase 2 setback for its geographic atrophy program, according to a source familiar with the decision. The company had planned to advance an eye drug toward Phase 3 this year despite the mid-stage clinical result. The shutdown highlights the funding and operational pressure that biotech companies face when efficacy or durability signals fail to materialize in Phase 2, particularly in areas where clinical endpoints and patient selection are tightly scrutinized. For the sector, the case is a reminder that even well-resourced development plans can quickly change direction once pivotal Phase 2 outcomes underperform.